Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) EV-to-EBITDA : -1.12 (As of May. 16, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Lixte Biotechnology Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lixte Biotechnology Holdings's enterprise value is $5.24 Mil. Lixte Biotechnology Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.67 Mil. Therefore, Lixte Biotechnology Holdings's EV-to-EBITDA for today is -1.12.

The historical rank and industry rank for Lixte Biotechnology Holdings's EV-to-EBITDA or its related term are showing as below:

LIXT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.21 Med: -5.56 Max: -1.1
Current: -1.12

During the past 13 years, the highest EV-to-EBITDA of Lixte Biotechnology Holdings was -1.10. The lowest was -30.21. And the median was -5.56.

LIXT's EV-to-EBITDA is ranked worse than
100% of 457 companies
in the Biotechnology industry
Industry Median: 9.79 vs LIXT: -1.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Lixte Biotechnology Holdings's stock price is $2.38. Lixte Biotechnology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.330. Therefore, Lixte Biotechnology Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Lixte Biotechnology Holdings EV-to-EBITDA Historical Data

The historical data trend for Lixte Biotechnology Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lixte Biotechnology Holdings EV-to-EBITDA Chart

Lixte Biotechnology Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-19.03

-11.58

-2.24

-1.05

-0.90

Lixte Biotechnology Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBITDA	Get a 7-Day Free Trial															-2.19	-1.69	-0.69	-0.90	-1.65

Competitive Comparison of Lixte Biotechnology Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Lixte Biotechnology Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lixte Biotechnology Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lixte Biotechnology Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lixte Biotechnology Holdings's EV-to-EBITDA falls into.

Lixte Biotechnology Holdings EV-to-EBITDA Calculation

Lixte Biotechnology Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	5.237	/	-4.67
	=	-1.12

Lixte Biotechnology Holdings's current Enterprise Value is $5.24 Mil.
Lixte Biotechnology Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.67 Mil.

Lixte Biotechnology Holdings (NAS:LIXT) EV-to-EBITDA Explanation

Lixte Biotechnology Holdings's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	2.38	/	-2.330
	=	At Loss

Lixte Biotechnology Holdings's share price for today is $2.38.
Lixte Biotechnology Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.330.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Lixte Biotechnology Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lixte Biotechnology Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Lixte Biotechnology Holdings (Lixte Biotechnology Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lixte Biotechnology Holdings Inc (NAS:LIXT) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

680 East Colorado Boulevard, Suite 180, Pasadena, CA, USA, 91101

Website

https://www.lixte.com

Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in combination with standard anti-cancer therapies, including cytotoxic drugs, radiation, and immune checkpoint blockers. The Company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and x-ray and immune checkpoint blockers.

Executives

Rene Bernards	director	KONINGSVAREN 37, ABCOUDE P7 1391AD
Van Der Baan Bastiaan Jeroen	director	HOGEWEG 4-H, AMSTERDAM P7 1098CB
Eric Forman	10 percent owner	117 E. 29TH ST., APT. 5A, NEW YORK NY 10016
Regina Brown	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Glenn Krinsky	10 percent owner	C/O SRKP 1, INC., 1900 AVENUE OF THE STARS, SUITE 310, LOS ANGELES CA 90067
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
Robert Greenberg	10 percent owner	SKECHERS USA INC, 228 MANHATTAN BEACH BLVD, MANHATTAN BEACH CA 90266
Gil Schwartzberg	10 percent owner	269 S. BEVERLY DR., #1315, BEVERLY HILLS CA 90212
Philip F Palmedo	director	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
John S Kovach	director, 10 percent owner, officer: Pres., CFO & Secty	1801 CENTURY PARK EAST #1600, LOS ANGELES CA 90067
Stephen J. Forman	director	248 ROUTE 25A, NO. 2, EAST SETAUKET NY 11733
Hung Tak Ho	10 percent owner	MAYFAIR BY THE SEA II, TOWER T8, 1/F, UNIT A, 21 FO CHUN ROAD, PAK SHEK KOK, TAIPO K3 00000
Robert N Weingarten	officer: Vice President and CFO	5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367
James Miser	officer: Chief Medical Officer	680 E COLORADO BLVD., SUITE 180, PASADENA CA 91101
Jane Merrill Riggs	10 percent owner	4852 SAINT ANDRES AVENUE, LA VERNE CA 91750